Cost effectiveness of treatments for inflammatory bowel disease

PharmacoEconomics

Volumn 29, Issue 5, 2011, Pages 387-401

  Bodger, Keith ^a  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

Adalimumab therapeutic use; Corticosteroids therapeutic use; Cost effectiveness; Crohns disease treatment; Inflammatory bowel diseases treatment; Infliximab therapeutic use; Mercaptopurine therapeutic use; Mesalazine therapeutic use; Methotrexate therapeutic use; Ulcerative colitis treatment

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PREDNISOLONE;

COLON CANCER; COLONOSCOPY; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DRUG EFFICACY; HEALTH CARE COST; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; ULCERATIVE COLITIS;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; COLONOSCOPY; COST-BENEFIT ANALYSIS; DIET THERAPY; HEALTH CARE COSTS; HUMANS; INFLAMMATORY BOWEL DISEASES; MESALAMINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79955076079     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11584820-000000000-00000     Document Type: Review

References (74)

1. Bodger K. Cost of illness of Crohns disease. Pharmacoeconomics 2002; 20 (10): 639-52
2. Luces C, Bodger K. Economic burden of inflammatory bowel disease: a UK perspective. Expert Rev Pharmacoeconomics Outcomes Res 2006; 6 (4): 471-82 (Pubitemid 44304755)
3. Yu AP, Cabanilla LA, Wu EQ, et al. The costs of Crohns disease in the United States and other Western countries: a systematic review. Curr Med Res Opin 2008; 24 (2): 319-28 (Pubitemid 351294380)
4. Jacobsen BA, Fallingborg J, Rasmussen HH, et al. Increase in incidence and prevalence of inflammatory bowel disease in northern Denmark: a population-based study, 1978-2002. Eur J Gastroenterol Hepatol 2006; 18 (6): 601-6 (Pubitemid 43804642)
5. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohns disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007; 5 (12): 1424-9 (Pubitemid 350181588)
6. Hay AR, Hay JW. Inflammatory bowel disease: medical cost algorithms. J Clin Gastroenterol 1992; 14 (4): 318-27
7. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohns disease: Markov model analysis of a population-based cohort. Gastroenterology 1999; 117 (1): 49-57 (Pubitemid 29297619)
8. Bassi A, Dodd S, Williamson P, et al. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004; 53 (10): 1471-8 (Pubitemid 39265268)
9. Bickston SJ, Waters HC, Dabbous O, et al. Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients. J Manag Care Pharm 2008; 14 (4): 352-62 (Pubitemid 351890850)
10. Blumenstein I, Bock H,Weber C, et al. Health care and cost of medication for inflammatory bowel disease in the Rhein- Main region, Germany: a multicenter, prospective, internet- based study. Inflamm Bowel Dis 2008; 14 (1): 53-60 (Pubitemid 351196869)
11. Cohen RD, Larson LR, Roth JM, et al. The cost of hospitalization in Crohns disease. Am J Gastroenterol 2000; 95 (2): 524-30
12. Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohns disease and ulcerative colitis. J Occup Environ Med 2008; 50 (11): 1261-72
13. Grogan JE, Smith MC. The economic cost of ulcerative colitis: a national estimate for 1968. Inquiry 1973; 10 (2): 61-8
14. Hay JW, Hay AR. Inflammatory bowel disease: costs-ofillness. J Clin Gastroenterol 1992; 14 (4): 309-17
15. Odes S, Vardi H, Friger M, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology 2006; 131 (3): 719-28 (Pubitemid 44307060)
16. Stark R, Konig HH, Leidl R. Costs of inflammatory bowel disease in Germany. Pharmacoeconomics 2006; 24 (8): 797-814 (Pubitemid 44232107)
17. Blomqvist P, Ekbom A. Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol 1997; 32 (11): 1134-9 (Pubitemid 27523846)
18. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohns disease and ulcerative colitis in US children and adults. Gastroenterology 2008; 135 (6): 1907-13
19. Williams JG, Cheung WY, Russell IT, et al. Open access follow up for inflammatory bowel disease: pragmatic randomised trial and cost effectiveness study. BMJ 2000; 320 (7234): 544-8 (Pubitemid 30175799)
20. Buckland A, Bodger K. The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis. Aliment Pharmacol Ther 2008; 28 (11-12): 1287-96
21. Hanauer SB, Sandborn WJ, Dallaire C, et al. Delayedrelease oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can J Gastroenterol 2007; 21: 827-34 (Pubitemid 351255702)
22. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayedrelease oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005; 100: 2478-85
23. Hanauer SB, Sandborn WJ, Kombluth A, et al. Modified release oral mesalazine 4.8 g/day (800 mg tablet) versus 2.4 g/day (400 mg tablet) for treatment of moderately active ulcerative colitis: combined analysis of two randomised, double-blind controlled trials. Gastroenterology 2005; 128 (4 Suppl. 2): A74-5, 492
24. Brereton N, Bodger K, Kamm MA, et al. A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis fromaUKperspective. JMed Econ 2010Mar; 13 (1): 148-61
25. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132: 66-75 (Pubitemid 46108735)
26. Yen EF, Kane SV, Ladabaum U. Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis. Am J Gastroenterol 2008; 103 (12): 3094-105
27. Mackowiak JI. A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of balsalazide versus mesalamine in the treatment of ulcerative colitis. Manag Care Interface 2006; 19 (10): 39-46, 56
28. Manson SC, Brown RE, Cerulli A, et al. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med 2009; 103 (7): 975-94
29. Kreck S, Klaus J, Leidl R, et al. Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model. Pharmacoeconomics 2008; 26 (4): 311-28 (Pubitemid 351457478)
30. Behm BW, Bickston SJ. Efficacy of infliximab for luminal and fistulizing Crohns disease and in ulcerative colitis. Curr Treat Options Gastroenterol 2007; 10 (3): 171-7 (Pubitemid 46938926)
31. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005 Dec 8; 353 (23): 2462-76 (Pubitemid 41770166)
32. Tsai HH, Punekar YS, Morris J, et al. A model of the longterm cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther 2008; 28 (10): 1230-9
33. Inadomi JM. Cost-effectiveness of colorectal cancer surveillance in ulcerative colitis. Scand J Gastroenterol Suppl 2003; (237): 17-21 (Pubitemid 36609873)
34. Provenzale D, Onken J. Surveillance issues in inflammatory bowel disease: ulcerative colitis. J Clin Gastroenterol 2001; 32 (2): 99-105 (Pubitemid 32113237)
35. Provenzale D, Wong JB, Onken JE, et al. Performing a costeffectiveness analysis: surveillance of patients with ulcerative colitis. Am J Gastroenterol 1998; 93 (6): 872-80 (Pubitemid 29076969)
36. Messori A, Brignola C, Trallori G, et al. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohns disease: a meta-analysis. Am J Gastroenterol 1994; 89 (5): 692-8 (Pubitemid 24132048)
37. Lofberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohns disease: a placebo controlled one year study. Gut 1996; 39 (1): 82-6 (Pubitemid 26239111)
38. Noble I, Brown R, Danielsson A, et al. Cost-effectiveness of budesonide Controlled Ileal Release (CIR) capsules as maintenance therapy versus no maintenance therapy for ileocaecal Crohns disease in Sweden. Clin Drug Investig 1998; 15 (2): 123-36 (Pubitemid 28101493)
39. Verma S, Brown S, Kirkwood B, et al. Polymeric versus elemental diet as primary treatment in active Crohns disease: a randomized, double-blind trial. Am J Gastroenterol 2000; 95 (3): 735-9 (Pubitemid 30123912)
40. Takahashi H, Ando T, Watanabe O, et al. Usefulness of an elemental diet in Crohns disease. Inflammopharmacology 2007; 15 (1): 15-7 (Pubitemid 46333881)
41. Ofman J, Koretz RL. Nutritional support: efficacy and costeffectiveness. In: Bodger K, Daly MJ, Heatley RV, editors. Clinical economics in gastroenterology. Oxford: Blackwell Science, 2000: 188-219
42. Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohns disease. Cochrane Database Syst Rev 2004; (1): CD003574
43. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohns disease. Cochrane Database Syst Rev 2008; (1): CD006893
44. Peyrin-Biroulet L, Deltenre P, de SN, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohns disease: meta-analysis of placebo-controlled trials. ClinGastroenterol Hepatol 2008; 6 (6): 644-53 (Pubitemid 351783447)
45. Joint Formulary Committee. British national formulary. 53 ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2008
46. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohns disease: the ACCENT I randomised trial. Lancet 2002; 359 (9317): 1541-9 (Pubitemid 34621118)
47. Lichtenstein GR, Yan S, Bala M, et al. Remission in patients with Crohns disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004; 99 (1): 91-6 (Pubitemid 38679108)
48. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohns disease. Gastroenterology 2004; 126 (2): 402-13 (Pubitemid 38182297)
49. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohns disease. N Engl J Med 2004; 350 (9): 876-85 (Pubitemid 38252535)
50. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohns disease. Gastroenterology 2005; 128 (4): 862-9 (Pubitemid 40523539)
51. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohns disease: the CHARM trial. Gastroenterology 2007; 132 (1): 52-65 (Pubitemid 46108762)
52. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohns disease: results from the CHARM study. Gastroenterology 2008; 135 (5): 1493-9
53. Jewell DP, Satsangi J, Lobo A, et al. Infliximab use in Crohns disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol 2005; 17 (10): 1047-52 (Pubitemid 41423997)
54. Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohns disease. J Clin Gastroenterol 2002; 35 (2): 151-6 (Pubitemid 34815854)
55. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohns disease: results from a single-centre cohort. Gut 2009; 58 (4): 492-500
56. Wailoo A, Tosh J. Use of tumour necrosis factor alpha (TNFA) inhibitors (adalimumab and infliximab) for Crohns disease. London: National Institute forHealth and Clinical Excellence, 2010 Jan 1
57. Arseneau KO, Cohn SM, Cominelli F, et al. Cost-utility of initial medical management for Crohns disease perianal fistulae. Gastroenterology 2001; 120 (7): 1640-56 (Pubitemid 32523483)
58. Marshall JK, Blackhouse G, Goeree R, et al. Clinical and economic assessment: infliximab for the treatment of Crohns disease: technology overview. Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 2002
59. Clark W, Raftery J, Song F, et al. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohns disease. Health Technol Assess 2003; 7 (3): 1-67
60. Jaisson-Hot I, Flourie B, Descos L, et al. Management for severe Crohns disease: a lifetime cost-utility analysis. Int J Technol Assess Health Care 2004; 20 (3): 274-9 (Pubitemid 39079562)
61. Lindsay J, Punekar YS, Morris J, et al. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohns disease: modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther 2008; 28 (1): 76-87 (Pubitemid 351782815)
62. Loftus Jr EV, Johnson SJ, Yu AP, et al. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohns disease. Eur J Gastroenterol Hepatol 2009 Nov; 21 (11): 1302-9
63. Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohns disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther 2009; 30 (3): 265-74
64. Ghosh S.Maintenance therapy versus episodic therapy with infliximab for Crohns disease. Nat Clin Pract Gastroenterol Hepatol 2004; 1 (2): 80-1 (Pubitemid 40823674)
65. National Institute for Health and Clinical Excellence. Appraisal consultation document: infliximab (review) and adalimumab for the treatment of Crohns disease (including a review of technology appraisal guidance 40). London: NICE 2008 [online]. Available from URL: http://www. nice.org.uk/guidance/index. jsp?action=article&o=45388 [Accessed 2010 Nov 25]
66. Lichtenstein GR. Infliximab: lifetime use for maintenance is appropriate in Crohns Disease. PRO: maintenance therapy is superior to episodic therapy. Am J Gastroenterol 2005; 100 (7): 1433-5 (Pubitemid 41032341)
67. Loftus EV. Infliximab: lifetime use for maintenance is appropriate in Crohns Disease. CON: lifetime use is an awfully long time. Am J Gastroenterol 2005; 100 (7): 1435-8
68. Wu EQ, Mulani PM, Yu AP, et al. Loss of treatment response to infliximab maintenance therapy in Crohns disease: a payor perspective. Value Health 2008; 11 (5): 820-9
69. Kelly CJ, Mir FA. Economics of biological therapies. BMJ 2009; 339: b3276
70. Office of Fair Trading. OFT report recommends reform to UK drug pricing scheme [press release; online]. Available from URL: http://www.oft.gov.uk/news- and-updates/press/ 2007/29-07 [Accessed 2010 Nov 25]
71. UK NHS, Department of Health. Equity and excellence: liberating the NHS. London: HMSO, 2010 Jul [online]. Available fromURL: http://www.dh.gov.uk/prod- consum- dh/groups/dh-digitalassets/@dh/@en/@ps/documents/ digitalasset/dh- 117794.pdf [Accessed 2010 Nov 25]
72. Baert F, Caprilli R,Angelucci E. Medical therapy for Crohns disease: top-down or step-up? Dig Dis 2007; 25 (3): 260-6 (Pubitemid 350194180)
73. Hanauer SB. Crohns disease: step up or top down therapy. Best Pract Res Clin Gastroenterol 2003; 17 (1): 131-7
74. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohns disease. N Engl J Med 2010; 362 (15): 1383-95